http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2013245526-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_067a3c5fff599aa564fefd4d03be8fde |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088 |
| filingDate | 2013-10-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df779b9a2ad235bcff26d6e71163f827 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9ae10795fc6e5308dc4eceff1e463534 |
| publicationDate | 2015-05-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AU-2013245526-A1 |
| titleOfInvention | Treatment of Cancers with Micro-RNA Inhibitors |
| abstract | The invention relates to the treatment and prevention of cancers, including blood-based cancers and breast cancers, by administering agents that inhibit the activity of microRNAs, including miR-22. Inhibitors can include oligonucleotides that are at least partially complementary to these miRNAs. In some embodiments, these inhibitors are chemically modified oligonucleotides, including locked nucleic acids (LNAs). |
| priorityDate | 2013-10-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 401.